$Vor Biopharma (VOR.US)$ Previously reported positive data on its gene editing stem cell therapy trem-cel for the treatment of acute myeloid leukemia (AML). The phase 1/2 trial data of the gene editing stem cell therapy trem-cel in combination with Mylotarg for the treatment of acute myeloid leukemia shows positive combined efficacy and potential drug safety.

It is understood that Vor Bio's Phase 1/2 study, named VBP101, is actively evaluating the efficacy of trem-cel in combination with Mylotarg, a pharmaceutical subsidiary of the U.S. pharmaceutical giant Pfizer (PFE.US), for the treatment of relapsed/refractory AML patients.

In a statement, Vor (VOR) stated that the research data "demonstrates reliable engraftment, shielding of Mylotarg's targeted toxicity, significantly broadening the therapeutic window of Mylotarg, and early evidence of broad patient benefit".

The company further stated that it plans to engage with the U.S. Food and Drug Administration (FDA) by the end of the year to discuss the core key trial design for the combination of trem-cel and Mylotarg treatment.

The core key trial is generally the final stage for approval of a new drug, which means that if these trials are successful, trem-cel is expected to quickly enter the market.

Vor also announced that the company is conducting a study that will allow another candidate therapy (an antibody-drug conjugate called VADC45) to enter Phase 1 testing. This diversified product pipeline progress demonstrates the company's R&D strength and long-term development potential in the field of cancer treatment.

The latest positive results from Vor Bio's collaboration with Pfizer's pharmaceutical trial indicate that trem-cel may have significant potential in future AML treatment, which also enhances investors' confidence in the company's prospects.

Gene editing therapy is considered one of the breakthrough therapies in the field of cancer treatment. As a research-stage company focused on developing innovative gene editing stem cell therapy, any subtle signs of clinical success from Vor Bio quickly catch the attention of investors and some speculative forces. Based on this, some investors are starting to have high expectations for the promising future of the trem-cel and Mylotarg combination.